Depressed or Not Depressed: Untangling Symptoms of Depression in Patients Hospitalized With Coronary Heart Disease

Eastwood, Jo‐Ann; Macabasco‐O'Connell, Aurelia; Doering, Lynn V.

doi:10.4037/ajcc2014146

Cited by 10 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixteen of the 21 articles were published in the past 5 years. More than half (60%) were cross-sectional studies [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] , while two were longitudinal prospective cohort studies 41,42 . Two articles used both cross-sectional and longitudinal study designs 1,24,40,43 .…”

Section: Characteristics Of the Selected Articlesmentioning

confidence: 99%

Disentangling fatigue from anhedonia: a scoping review

2020

View full text Add to dashboard Cite

Fatigue and anhedonia are commonly reported, co-occurring clinical symptoms associated with chronic illnesses. Fatigue is a multidimensional construct that is defined as a distressing, persistent, subjective sense of physical, cognitive, or emotional tiredness that interferes with usual functioning. Anhedonia is a component of depressive disorders and other psychiatric conditions, such as schizophrenia, and is defined by the reduced ability to experience pleasure. Both symptoms greatly affect the health-related quality of life of patients with chronic illnesses. Although fatigue and anhedonia are commonly associated with each other, understanding the differences between the two constructs is necessary for diagnosis and clinical treatment. A scoping review was conducted based on published guidance, starting with a comprehensive search of existing literature to understand the similarities and differences between fatigue and anhedonia. An initial search of PubMed using fatigue and anhedonia as medical subject headings yielded a total of 5254 articles. A complete full-text review of the final 21 articles was conducted to find articles that treated both constructs similarly and articles that presented fatigue and anhedonia as distinct constructs. About 60% of the reviewed articles consider both constructs as distinct, but a considerable number of the reviewed articles found these constructs indistinguishable. Nomenclature and biology were two themes from the reviewed articles supporting the idea that anhedonia and fatigue are indistinguishable constructs. The information generated from this review is clinically relevant to optimize the management of fatigue related to anhedonia from other fatigue subtypes.

show abstract

Section: Characteristics Of the Selected Articlesmentioning

confidence: 99%

Disentangling fatigue from anhedonia: a scoping review

2020

View full text Add to dashboard Cite

show abstract

“…Finally, because medical comorbidities can complicate depression screening and diagnosis, clinicians should be aware of their role in both under- or misdiagnosis of MDD ( Huerta-Ramirez et al, 2013 ; McGuire et al, 2014 ). Depression symptoms may be missed in patients presenting with symptoms of comorbid conditions, resulting in delayed diagnosis and treatment ( McGuire et al, 2014 ; Lam et al, 2016 ; Thase, 2016 ). Likewise, not ruling out the presence of another psychiatric disorder, such as obsessive-compulsive disorder, posttraumatic stress disorder, or bipolar disorder, when a patient presents with depression commonly results in treatment-resistance because the comorbid condition is inappropriately or inadequately treated.…”

Section: How Does the Clinician Provide Early Optimized Treatment Formentioning

confidence: 99%

Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient

Oluboka

Katzman

Habert

et al. 2017

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

Major depressive disorder is an often chronic and recurring illness. Left untreated, major depressive disorder may result in progressive alterations in brain morphometry and circuit function. Recent findings, however, suggest that pharmacotherapy may halt and possibly reverse those effects. These findings, together with evidence that a delay in treatment is associated with poorer clinical outcomes, underscore the urgency of rapidly treating depression to full recovery. Early optimized treatment, using measurement-based care and customizing treatment to the individual patient, may afford the best possible outcomes for each patient. The aim of this article is to present recommendations for using a patient-centered approach to rapidly provide optimal pharmacological treatment to patients with major depressive disorder. Offering major depressive disorder treatment determined by individual patient characteristics (e.g., predominant symptoms, medical history, comorbidities), patient preferences and expectations, and, critically, their own definition of wellness provides the best opportunity for full functional recovery.

show abstract

“…This data suggested that regulation of 5-HT1A receptor participated in the development of depression through control of central cholesterol in rats. In patients with coronary artery disease, the prevalence of several diseases has been increased, such as type 2 diabetes mellitus [ 35 , 36 ] and symptoms of depression [ 37 ], leading to increased risk for further cardiac events after acute coronary syndrome. Moreover, about 17%–27% of patients with coronary artery disease have major depression, and a significantly larger percentage have subsyndromal symptoms of depression [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Reduced cholesterol is associated with the depressive-like behavior in rats through modulation of the brain 5-HT1A receptor

et al. 2015

View full text Add to dashboard Cite

BackgroundLow serum cholesterol levels are related to an increased risk of depression and its serious consequences. However, the effect of central cholesterol on depressive disorder and its potential regulatory mechanism is poorly understood. Therefore, brain cholesterol in patients with depression may not only decrease the risk for developing this disease but also increase the beneficial effects of treatment for depression.MethodsIn current study, rats were exposed to chronic mild stress (CMS) for consecutive 28 days, and the depressive-like behavior was tested by sucrose preference test, immobility in the forced swim test, locomotor activity in the open field test, decreased bodyweight and food intake. Additionally, the total cholesterol levels in the medial prefrontal cortex (mPFC) and the hippocampus of rats were measured by gas chromatograph mass spectrometer. Finally, 5-HT1A receptor antagonist WAY100635 was used to determine the potential role of serotonin system in the interaction between central cholesterol and depression.ResultsCMS significantly reduced total cholesterol levels in the mPFC but not in the hippocampus and resulted in depressive-like behavior. Chronic supplementation of cholesterol by food reversed the depressive-like behavior induced by CMS. Furthermore, pre-injection of 5-HT1A receptor antagonist WAY100635 into the mPFC blocked the treatment effects of cholesterol on the reversal of behavioral response.ConclusionThis finding suggested that cholesterol in the mPFC may have an impact on the sensitivity of the 5-HT1A receptor in the development and treatment of depression. The treatment benefits of cholesterol could be through modulation of the brain 5-HT1A receptor.

show abstract

Depressed or Not Depressed: Untangling Symptoms of Depression in Patients Hospitalized With Coronary Heart Disease

Cited by 10 publications

References 41 publications

Disentangling fatigue from anhedonia: a scoping review

Disentangling fatigue from anhedonia: a scoping review

Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient

Reduced cholesterol is associated with the depressive-like behavior in rats through modulation of the brain 5-HT1A receptor

Contact Info

Product

Resources

About